Racura Oncology doses first patient in trial of RC220 + doxorubicin for solid tumours
Racura Oncology doses first patient in trial of RC220 + doxorubicin for solid tumours
Racura Oncology Ltd (ASX:RAC, OTC:RAONF) has successfully dosed the first patient with the combination of its lead drug RC220 and doxorubicin in its Phase 1 clinical trial targeting advanced solid tumours. Read the full article...
The Australian: Racura Oncology doses first patient in RC220 Phase 1 solid tumour trial
The Australian: Racura Oncology doses first patient in RC220 Phase 1 solid tumour trial
The Australian reports Racura Oncology has achieved a major milestone, as the company has safely and successfully dosed its first patients for its Phase 1 clinical trial in advanced solid tumours. Read the full...
ausbiz: Racura to better cancer treatment
ausbiz: Racura to better cancer treatment
Racura CEO and Managing Director Dr Daniel Tillett speaks with ausbiz about the company’s recent major milestone – the first patient has been safely and successfully dosed for the RC220 Phase 1 clinical trial...
Racura Oncology launches Phase I RC220 trial in Australia
Racura Oncology launches Phase I RC220 trial in Australia
Racura Oncology CEO and MD Daniel Tillett speaks with Proactive about the activation of the first Australian clinical site for the RC220 Phase I solid tumour trial. Dr Tillett confirms that the trial is...
Stockhead reports Racura gets ethics nod for Phase I trial in solid tumour patients
Stockhead reports Racura gets ethics nod for Phase I trial in solid tumour patients
Racura Oncology Executive Chair Dr Peter Smith speaks with Stockhead about the recent ethics approval for the company’s RC220 bisantrene Phase 1 clinical trial in solid tumour. The full report can be accessed via...
Proactive: Racura Oncology’s RC220 trial gets green light
Proactive: Racura Oncology’s RC220 trial gets green light
Racura Oncology Executive Chair Dr Peter Smith speak with Proactive about the approval the company has received from the Bellberry Human Research Ethics Committee (HREC). The approval allows the company to move forward with...
ausbiz speaks with Racura CEO on the Phase 1 trial ethics approval
ausbiz speaks with Racura CEO on the Phase 1 trial ethics approval
Racura CEO and Managing Director Dr Daniel Tillett speaks with ausbiz’s Juliette Saly about the ethics approval for the RC220 bisantrene Phase 1 clinical trial. Watch the full video via this link....
Proactive – Daniel Tillett on Racura Oncology’s drug advancements
Proactive – Daniel Tillett on Racura Oncology’s drug advancements
Racura CEO and Managing Director Dr Daniel Tillett speaks with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Dr Tillett discussed the challenges of chemotherapy, including severe...
Proactive: Oncology market projected to soar in 2025 and beyond
Proactive: Oncology market projected to soar in 2025 and beyond
Proactive reports on the outlook of the oncology therapeutics market, naming Racura Oncology, alongside its peer companies, one of the most promising to look out for. Read the full article via this link....
Road to 2025: Racura on track with clinical trials
Road to 2025: Racura on track with clinical trials
Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Fraser Palamara takes a look at Racura Oncology (ASX:RAC)....
